Skip to Content

Join the 'Aripiprazole' group to help and get support from people like you.

Aripiprazole News

FDA Approves Aristada Initio (aripiprazole lauroxil) for the Initiation of Aristada for Schizophrenia

Posted 3 Jul 2018 by Drugs.com

DUBLIN, July 2, 2018 /PRNewswire/ – Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Aristada Initio (aripiprazole lauroxil) for the initiation of Aristada (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. For the first time, Aristada Initio, in combination with a single ...

Do Antipsychotic Meds for Kids Raise Diabetes Risk?

Posted 13 Jun 2018 by Drugs.com

WEDNESDAY, June 13, 2018 – Widely used antipsychotic medications for troubled kids and teens can trigger weight gain and decrease insulin sensitivity, putting them at increased risk for diabetes, according to a new study. Antipsychotic medications are used in youngsters to treat nonpsychotic disorders associated with disruptive behavior, such as attention deficit hyperactivity disorder (ADHD), ...

FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication

Posted 14 Nov 2017 by Drugs.com

November 13, 2017 – The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated ...

FDA OKs First 'Digital Pill', Abilify Mycite, That Lets Doctors Know It's Been Taken

Posted 14 Nov 2017 by Drugs.com

TUESDAY, Nov. 14, 2017 – Offering both the promise of better patient compliance with health care, but also fears of a medical "Big Brother," a newly approved "digital pill" allows physicians to track whether or not it's been ingested by patients. The U.S. Food and Drug Administration has given the nod to Abilify MyCite, for use in patients with schizophrenia, an add-on treatment for depression, ...

'Digital Pill', Abilify Mycite, Tells Doctor When Patient Takes It

Posted 14 Nov 2017 by Drugs.com

TUESDAY, Nov. 14, 2017 – The first drug designed to alert a doctor when a patient takes the medication has been approved by the U.S. Food and Drug Administration. Abilify MyCite (aripiprazole with sensor) has an embedded sensor that sends a message to a wearable patch that the medication's been taken. This allows the patient and doctor to track the medication's use via smartphone. Abilify, first ...

Genes May Explain Why Some Don't Respond to Bipolar Drug

Posted 8 Nov 2017 by Drugs.com

WEDNESDAY, Nov. 8, 2017 – In a finding that pulls the roots of two mental illnesses closer together, researchers say people with bipolar disorder that's resistant to the drug lithium have a high number of genes associated with schizophrenia. Since the 1950s, lithium has been widely used to treat bipolar disorder. The drug stabilizes mood swings – the highs and lows associated with the disorder ...

Magnetic Brain Stimulation May Quiet 'Voices' in Schizophrenia

Posted 7 Sep 2017 by Drugs.com

THURSDAY, Sept. 7, 2017 – A therapy that stimulates a region of the brain linked to language may help quiet the hallucinatory "voices" that often plague schizophrenia patients, new research suggests. A voice hallucination "seems very real for the patient, and very disturbing," explained study author Dr. Sonia Dollfus. "The voices can be felt inside or outside the brain." Dollfus is head of the ...

Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by the U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder

Posted 8 Aug 2017 by Drugs.com

Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena® (aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and Drug Administration for the maintenance monotherapy treatment of bipolar I disorder (BP I) in adults1. Abilify Maintena is a once-monthly injectable ...

FDA Approves Two-Month Aristada for Treatment of Schizophrenia

Posted 7 Jun 2017 by Drugs.com

DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. Aristada is now FDA-approved in four doses and three dosing duration options (441 mg, 662 mg or 882 mg once monthly, 882 mg once every ...

Chronic Pain Common in Adults With Depression, Anxiety

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Chronic pain afflicts about half of adults who have anxiety or depression, a new study finds. More than 5,000 adults in Brazil diagnosed with anxiety or mood disorders such as depression and bipolar disorder were asked about other health problems. Among those with a mood disorder, half reported chronic pain; 33 percent, respiratory diseases; 10 percent, heart disease; 9 ...

'Recovery-Oriented' Talk Therapy May Help Curb Schizophrenia

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – A type of talk therapy may provide lasting benefits for schizophrenia patients, a new study suggests. This approach is called recovery-oriented cognitive therapy. The study of 60 patients found those who received this therapy showed major improvements compared to those who received standard treatment, said researcher Paul Grant and his colleagues at the University of ...

Nearly a Third of Drugs Hit by Safety Issues After FDA Approval

Posted 10 May 2017 by Drugs.com

WEDNESDAY, May 10, 2017 – Safety problems emerge with nearly one in three prescription drugs after they've been approved by the U.S. Food and Drug Administration, a new study reveals. Researchers examined data on drugs approved by the FDA between 2001 and 2010, with follow-up through 2017. The investigators found that 32 percent of the drugs had safety issues after approval. "That is very rarely ...

Nursing Home Program Offers Alternatives to Antipsychotic Drugs

Posted 20 Apr 2017 by Drugs.com

THURSDAY, April 20, 2017 – Hoping to cut the use of antipsychotic drugs in nursing home residents, researchers tried training staff on new ways to meet the needs of residents with dementia. Although antipsychotics are often given to people with dementia, the drugs are only minimally effective at controlling behavioral problems and have been shown to increase the chances for stroke and death, the ...

FDA Warns Against Bogus Autism 'Cures'

Posted 12 Apr 2017 by Drugs.com

WEDNESDAY, April 12, 2017 – Don't fall for products claiming to cure autism, the U.S. Food and Drug Administration warns. There's no cure for the neurodevelopmental disorder, the agency said. Yet bogus "cures" and therapies abound – from toxin removal to raw camel milk. Some of these fraudulent treatments could be harmful, and should be avoided, the agency said Wednesday. Among them: chelation ...

Patients Often Reject Drug-Only Psychiatric Treatment

Posted 6 Mar 2017 by Drugs.com

MONDAY, March 6, 2017 – Mental health patients are more likely to reject treatment if it involves only drugs, a new study finds. Some experts believe talk therapy should be the first treatment option for many mental health disorders. The new finding – from a review of 186 prior studies – supports that stance, the researchers said. "Patients often desire an opportunity to talk with and work ...

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Bipolar Disorder, Depression, Autism, Schizoaffective Disorder, Agitated State, Schizophrenia, Borderline Personality Disorder, Major Depressive Disorder, Obsessive Compulsive Disorder, Post Traumatic Stress Disorder, Tourette's Syndrome

Related Drug Support Groups

Abilify, Abilify Maintena, Abilify Discmelt, Abilify MyCite, Aristada

Aripiprazole Patient Information at Drugs.com